Optimal therapy for chronic hepatitis B: Hepatitis B virus combination therapy?

Liver International

Volumn 35, Issue s1, 2015, Pages 114-120

  Petersen, Jorg ^a   Dandri, Maura ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

CccDNA; Combination therapy; HBsAg; HBsAg loss; NUC; PEGIFN

Indexed keywords

ANTIVIRAL AGENTS; DNA, CIRCULAR; ENTECAVIR; GUANINE; HEPATITIS B SURFACE ANTIGENS; INTERFERON-ALPHA; PEGINTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; DRUG THERAPY, COMBINATION; GENETICS; HEPATITIS B, CHRONIC; HUMANS; METHODS; TRANSCRIPTION, GENETIC; TRENDS; VIRAL LOAD;

ANTIVIRAL AGENTS; DNA, CIRCULAR; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TRANSCRIPTION, GENETIC; VIRAL LOAD;

EID: 84919627857     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12720     Document Type: Review

References (33)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
2. Levrero M, Pollicino T, Petersen J, et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-92.
3. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int 2014; 34: 97-107.
4. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
5. Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol 2013; 58: 205-9.
6. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-8.
7. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008; 134: 235-49.
8. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
9. Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133: 843-52.
10. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-84.
11. Lutgehetmann M, Volzt T, Quaas A, et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008; 13: 57-66.
12. Belloni L, Allweiss L, Guerrieri F, et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012; 122: 529-37.
13. Dandri M, Petersen J. Hepatitis B virus cccDNA clearance: killing for curing? Hepatology 2005; 42: 1453-5.
14. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61: i6-17.
15. Chevaliez S, Hézode C, Bahrami S, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013; 58: 676-83.
16. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-608.
17. Addison WR, Walters KA, Wong WW, et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 2002; 76: 6356-63.
18. Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000; 32: 139-46.
19. Mason WS, Jilbert AR, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci U S A 2005; 102: 1139-44.
20. Lutgehetmann M, Volz T, Kopke A, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010; 52: 16-24.
21. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-8.
22. Allweiss L, Volz T, Lutgehetmann M, et al. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J Hepatol 2014; 60: 500-7.
23. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa 2a HBeAg-positive chronic Hepatitis B study group. Peginterferon alfa 2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
24. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa 2a HBeAg-negative chronic Hepatitis B study group. Peginterferon alfa 2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
25. Takkenberg RB, Jansen L, de Niet A, et al. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon alpha 2a and adefovir. Antivir Ther 2013; 18: 895-904.
26. Jansen L, de Niet A, Stelma F, et al. HBsAg loss in patients with peginterferon alfa 2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. J Hepatol 2014; Available at http://dx.doi.org/10.1016/j.jhep.2014.05.004. Accessed: 23 September 2014.
27. Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding Peginteferon to entecavir increases response rates in HBeAg-positive CHB patients: week 96 results of a global multicenter randomised trial (ARES study). J Hepatol 2014; 60: S2.
28. Xie Q, Zhou H, Bai X, et al. A randomized, open-label clinical study of combined Peginterferon alfa-2a (40kD) and entecavir treatment for HBeAg-positive chronic Hepatitis B. Clin Infect Dis 2014; pii: ciu702. [Epub ahead of print]
29. Marcellin P, Wursthorn K, Wedemeyer H, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B was associated with unexpected high rate of peripheral neuropathy. J Hepatol 2014; Available at http://dx.doi.org/10.1016/j.jhep.2014.08.021. Accessed: 23 September 2014.
30. Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegINf alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized open-label trial (OSST trial). J Hepatol 2014; Available at http://dx.doi.org/10.1016/j.jhep.2014.05.044. Accessed: 23 September 2014.
31. Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012; 56: 520-6.
32. Petersen J, Unger J, Buti M, et al. Add-on therapy with entecavir plus tenofovir due to viral resistance or partial responses followed by mono-therapy in CHB-patients: final results from an international multicentre study. J Hepatol 2014; 60: S440.
33. Marcellin P, Ahn SH, Ma X, et al. HBsAg loss with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2a (PEG) in chronic hepatitis B (CHB): results of a global randomized controlled trial. Hepatol 2014; 60(Suppl): 294A.